Literature DB >> 28833445

In silico mapping of allosteric ligand binding sites in type-1 cannabinoid receptor.

Annalaura Sabatucci1, Daniel Tortolani2, Enrico Dainese1,3, Mauro Maccarrone3,4.   

Abstract

The recent resolution of the crystal structure of type-1 cannabinoid receptor (CB1 ) and the discovery of novel modulators for this target open the way to the possibility of elucidating the structural requirements for CB1 binding, and thereby facilitate a rational drug design. Compounds that target the orthosteric site of CB1 in some cases have shown side effects. Allosteric modulators could potentially avoid these side effects by influencing binding and/or efficacy of orthosteric ligands. Here, we summarize and compare previous data on different putative allosteric binding sites observed in CB1 homology models with an in silico docking study of the recently published crystal structure of the same receptor on endogenous and natural hydrophobic ligands that act as positive allosteric modulators and negative allosteric modulators of CB1 . In particular, a lipid-exposed pocket targeted by most of the tested molecules is reported and discussed.
© 2017 International Union of Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  CB1 binding; allosteric modulators; in silico mapping

Mesh:

Substances:

Year:  2018        PMID: 28833445     DOI: 10.1002/bab.1589

Source DB:  PubMed          Journal:  Biotechnol Appl Biochem        ISSN: 0885-4513            Impact factor:   2.431


  9 in total

Review 1.  Extramembranous Regions in G Protein-Coupled Receptors: Cinderella in Receptor Biology?

Authors:  Sreetama Pal; Amitabha Chattopadhyay
Journal:  J Membr Biol       Date:  2019-08-30       Impact factor: 1.843

Review 2.  Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention.

Authors:  F Markus Leweke; Juliane K Mueller; Bettina Lange; Stefan Fritze; Cristina E Topor; Dagmar Koethe; Cathrin Rohleder
Journal:  CNS Drugs       Date:  2018-07       Impact factor: 5.749

3.  Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors.

Authors:  Mylyne Tham; Orhan Yilmaz; Mariam Alaverdashvili; Melanie E M Kelly; Eileen M Denovan-Wright; Robert B Laprairie
Journal:  Br J Pharmacol       Date:  2018-08-10       Impact factor: 8.739

4.  Allosteric Modulation of the CB1 Cannabinoid Receptor by Cannabidiol-A Molecular Modeling Study of the N-Terminal Domain and the Allosteric-Orthosteric Coupling.

Authors:  Jakub Jakowiecki; Renata Abel; Urszula Orzeł; Paweł Pasznik; Robert Preissner; Sławomir Filipek
Journal:  Molecules       Date:  2021-04-23       Impact factor: 4.411

Review 5.  Anandamide Revisited: How Cholesterol and Ceramides Control Receptor-Dependent and Receptor-Independent Signal Transmission Pathways of a Lipid Neurotransmitter.

Authors:  Coralie Di Scala; Jacques Fantini; Nouara Yahi; Francisco J Barrantes; Henri Chahinian
Journal:  Biomolecules       Date:  2018-05-22

Review 6.  Endocannabinoids in Body Weight Control.

Authors:  Henrike Horn; Beatrice Böhme; Laura Dietrich; Marco Koch
Journal:  Pharmaceuticals (Basel)       Date:  2018-05-30

Review 7.  Cannabinoids and Cannabinoid Receptors: The Story so Far.

Authors:  Fred Shahbazi; Victoria Grandi; Abhinandan Banerjee; John F Trant
Journal:  iScience       Date:  2020-06-20

Review 8.  Novel approaches and current challenges with targeting the endocannabinoid system.

Authors:  Paula Morales; Nadine Jagerovic
Journal:  Expert Opin Drug Discov       Date:  2020-04-27       Impact factor: 7.050

Review 9.  Biosynthesis of Nature-Inspired Unnatural Cannabinoids.

Authors:  Kevin J H Lim; Yan Ping Lim; Yossa D Hartono; Maybelle K Go; Hao Fan; Wen Shan Yew
Journal:  Molecules       Date:  2021-05-14       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.